Theraclone Sciences is a technology company.
Theraclone Sciences has raised $44.0M across 4 funding rounds.
Theraclone Sciences has raised $44.0M in total across 4 funding rounds.
Theraclone Sciences has raised $44.0M in total across 4 funding rounds.
Theraclone Sciences's investors include ARCH Venture Partners, Canaan Partners, Domain Associates.
Theraclone Sciences has raised $44.0M across 4 funding rounds. Most recently, it raised $8.0M Series B in March 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2013 | $8.0M Series B | ARCH Venture Partners, Canaan Partners, Domain Associates | |
| Mar 1, 2010 | $2.0M Venture Round | ARCH Venture Partners, Canaan Partners, Domain Associates | |
| Mar 1, 2007 | $29.0M Series B | ARCH Venture Partners, Canaan Partners, Domain Associates | |
| Mar 1, 2006 | $5.0M Series A | ARCH Venture Partners |
Theraclone Sciences is a biopharmaceutical company specializing in the discovery and development of human monoclonal antibodies for treating infectious diseases and cancer.[1][2][3] It leverages proprietary screening technology, I-STARTM, to identify rare, fully human antibodies from immunologically relevant subjects, targeting infections like HIV and influenza, as well as oncology applications.[1][3] The company, based in Seattle, Washington, has raised $63.75M in Series C funding, with its last round in 2015, and has licensed key assets including HIV antibodies to Gilead for cure regimens and its platform to OncoResponse for oncology.[1][2][3] It serves pharmaceutical partners and patients by addressing unmet needs in antibody therapeutics, though no products have reached market approval based on available data, with pipelines like PGT-121 in Phase 1/2 for HIV.[6]
Founded on March 16, 2004, as Intragenex Inc. in Seattle, Theraclone Sciences evolved into a discovery-stage biotech focused on therapeutic antibodies for infectious diseases and inflammation.[4][5] Key early leaders included CEO Clifford J. Stocks, President Russ Hawkins, and Member Steven Gillis, who guided its development over two decades.[4] The idea emerged from advancing screening technologies to rapidly identify rare antibodies from the human immune system, perfected over a decade of research.[2][3] Pivotal moments include licensing HIV broadly neutralizing antibodies to Gilead for an HIV-cure regimen and its I-STARTM platform to OncoResponse for oncology, demonstrating early traction despite remaining in Series C stage.[1][3]
Theraclone rides the wave of antibody discovery innovation in biotech, particularly for hard-to-treat infectious diseases like HIV and emerging viruses, amid rising demand for monoclonal antibodies post-COVID.[1][3][6] Timing aligns with advances in immune repertoire sequencing and AI-driven screening, amplifying platforms like I-STARTM to accelerate rare antibody identification.[2][3] Market forces favoring it include surging oncology antibody deals (e.g., its OncoResponse license) and persistent needs for HIV cures, with global antibody markets projected to grow amid antibiotic resistance and pandemics.[1][6] It influences the ecosystem by validating human screening tech through partnerships, enabling spinouts like OncoResponse and contributing to broader antibody pipelines without direct commercialization.[3]
Theraclone's licensed assets position it for milestone payments and royalties from partners like Gilead and OncoResponse, potentially funding new infectious disease or oncology programs.[1][3] Trends like next-gen antibody engineering and mRNA-boosted immunity could revitalize its dormant pipelines (e.g., reviving influenza or CMV candidates), while biotech M&A might lead to acquisition.[6] Its influence may evolve through platform expansions or new licenses, sustaining impact in antibody therapeutics despite limited recent activity—echoing its core strength in uncovering nature's rare cures from the human immune system.[2][3]